Joy Tang is an Oncology physician. OpenAlex indexes 13 publications with 328 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
810 Jasonway Ave Ste A
Columbus, OH 432144359
Telephone
614-442-3130Provider last certified this registry record 13 Jan 2025.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- Incyte CorporationProgram year20234 payments
- BeiGene USA, Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
82.2%Other antiemetics67.2%Fosaprepitant100%Part B, office-administered≥12 patientsSerotonin-3 Receptor Antagonist14%Palonosetron hcl63%Granisetron hydrochloride37%Part B, office-administered≥19 patients+ 2 more classes in this area
Sensory organs
12.9%Corticosteroid12.9%Dexamethasone sodium phosphate98%Dexamethasone2%Part D + Part B<11 patientsCancer & immunology
3.4%Aromatase Inhibitor2.1%Anastrozole100%Part D≥33 patientsKinase inhibitor0.7%Imbruvica68%Fotivda32%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
Expert Review of Anticancer Therapy
2022 - Stem cell damage after chemotherapy- can we do better?
Best Practice & Research Clinical Haematology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”